ReviewDiscover nano2026
Global research trends and emerging frontiers of nanozymes in cancer therapy based on bibliometric and knowledge mapping analysis from 2001 to 2025.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCancer remains one of the leading causes of mortality worldwide, posing major clinical and societal challenges because of the limitations of conventional therapies and the emergence of treatment resistance. In recent years, nanozymes-nanomaterials with intrinsic enzyme-like activities-have emerged as promising therapeutic agents for cancer treatment because of their high stability, tunable catalytic properties, and ability to modulate the tumor microenvironment (TME). However, a comprehensive assessment of the research landscape in this field remains lacking.
methodsA bibliometric analysis was conducted on 2657 English-language publications related to nanozyme-based cancer therapy published between 2001 and 2025, retrieved from the Web of Science Core Collection (WoSCC) and Scopus databases. CiteSpace, VOSviewer, and the bibliometrix R package were employed to analyze publication trends, global contributions, collaboration networks, keyword evolution, and emerging research frontiers.
resultsResearch on nanozyme-based cancer therapy has experienced exponential growth since 2017. China leads in terms of publication volume, whereas Singapore and the United States demonstrate higher citation impact. Major research hotspots include modulation of the tumor microenvironment (TME), catalytic combination therapy, single-atom nanozymes (SANs), and various programmed cell death pathways, including apoptosis, ferroptosis, pyroptosis, and immunogenic cell death (ICD). Nanozymes markedly enhance photothermal, photodynamic, chemodynamic, and sonodynamic therapies. This enhancement is achieved through the regulation of reactive oxygen species (ROS) and the stimulation of immune responses. Despite these advances, several challenges remain, including standardization of synthesis, tumor-targeting specificity, and long-term biosafety.
conclusionNanozymes are transforming the landscape of cancer therapy by facilitating multimodal, immune-responsive, and precision-targeted strategies. Future research should prioritize the optimization of design and safety, the enhancement of international collaboration, and the advancement of clinical translation to fully realize their potential in next-generation oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.